Biomarker Validation

There's sometimes a misconception that biomarcs are often termed exploratory, because they're not yet established primary end pointser for regulatory purposes. People misunderstand this in the terms that kind of the analysis aimless, that we just measure them and thenbut let's just have a look and see if we a signal pups up. And i think it is a very wide field that starts kind ofate technical, analytical validation to make sure that you can reproduce it. But also from a statistical or regulatory point of view, having maybe a correlation to a clinical end point when it comes to phamaco dynamic effect.